LCGC
REGN icon

Legacy Capital Group California’s Regeneron Pharmaceuticals REGN Stock Holding History

Legacy Capital Group California’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$335K Buy
+537
New +$366K 0.1% 253
2026
Q1 		– Sell
-1,716
Closed -$1.32M – 346
2025
Q4 		$1.32M Buy
+1,716
New +$1.17M 0.32% 71

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Legacy Capital Group California's REGN Position: Q2 2026 in Review

Legacy Capital Group California opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 537 shares worth $335K. The stake represents 0.1% of the portfolio and ranks #253 among its holdings. This is a return to the name: Legacy Capital Group California previously reported a position in REGN as recently as Q4 2025.

Legacy Capital Group California first reported a position in REGN in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.32M in Q4 2025. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Legacy Capital Group California held 537 shares of Regeneron Pharmaceuticals worth $335K as of Q2 2026.
  • Regeneron Pharmaceuticals was a new Legacy Capital Group California position in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.1% of Legacy Capital Group California's portfolio in Q2 2026, its #253 holding.
  • Legacy Capital Group California first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Legacy Capital Group California's Regeneron Pharmaceuticals position peaked at $1.32M in Q4 2025.
  • 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Legacy Capital Group California's 13F filing for Q2 2026, filed 29 Jul 2026.